Being that Donald Trump has tapped Tom Price as his secretary of Health and Human Services and SeemaVerma to head up the Centers for Medicare and Medicaid Services, it’s safe to say the healthcare system is poised to undergo some serious changes in the very near future.
This is because Donald Trump and his administration are fixated on the idea of lowering the cost of healthcare in the United States. And from the looks of it, they are willing to do almost anything to make sure this happen.
Right now Trump is proposing the red tape at the FDA be cut so that Abbreviated New Drug Applications (ANDAs) for generic drugs can be reviewed and approved at a much quicker rate.
Right now, due to the unbelievable number of generic drug submissions received by the FDA on a regular basis, there is a backlog of about 3,000 Abbreviated New Drug Applications (ANDAs) that are waiting to be reviewed.
If Trump has his way and the red tape is cut, you can expect a sharp increase in the number of generic drugs that make their way onto the market. To benefit from this sharp increase it would be a smart move to buy stock in Teva Pharmaceutical Industries Ltd, one of the largest generic drug companies in the world.
In mid 2016 Teva Pharmaceutical Industries Ltd acquired the generic drug unit of Allergan for billions of dollars. This one move put them in the position to shape how generic drugs will be priced for the foreseeable future.
Currently Teva Pharmaceutical Industries Ltd has about 300 Abbreviated New Drug Applications (ANDAs) on file with the FDA. That means if certain healthcare reforms should take place, they would be one of the biggest potential beneficiaries of those reforms.
But here is what will make investing in Teva right now not only a smart move, but a very profitable one as well. Of the 300 or so Abbreviated New Drug Applications (ANDAs) they currently have on file with the FDA, one third of them are first generic drugs.
First generic drugs are the first generic versions of some of the most popular branded drugs currently on the market. First generic drugs, being that they are the first of their kind, tend to have a period of exclusivity when they first hit the market. During that short window you can make a ton of money if you are invested in the company.